Reduced radiation dose for anal cancer treatment

REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation

This study is testing if giving a lower dose of radiation during anal cancer treatment can reduce side effects while still being effective for patients.

Quick facts

• Phase: Phase2; Phase3
• Study type: Interventional
• Enrollment: 33 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: University of Cincinnati (Academic / other)
• Drugs / interventions: radiation
• Locations: 3 sites (Cincinnati, Ohio and 2 other locations)
• Trial ID: NCT05902533 on ClinicalTrials.gov

What this trial studies

This clinical trial evaluates the effectiveness of a reduced elective nodal radiation dose of 30.6 Gy in patients with anal cancer undergoing chemoradiation. It is a multi-center, single-arm prospective trial that aims to compare the toxicity levels experienced by participants to those of historical patients treated with standard nodal doses. The study will assess toxicity using the CTCAE Toxicity Index and patient-reported outcomes for gastrointestinal toxicity. The goal is to determine if the reduced dose can mitigate side effects while maintaining treatment efficacy.

Who should consider this trial

Good fit: Ideal candidates include adults aged 18 and older with locally advanced anal cancer (stage T1-4N+M0 or T3/T4N0M0) who meet specific imaging criteria.

Not a fit: Patients with early-stage anal cancer (Stage I or II with tumors ≤ 4 cm) will not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could significantly reduce treatment-related toxicity for anal cancer patients.

How similar studies have performed: While this approach is innovative, similar studies have shown promise in reducing toxicity in cancer treatments, suggesting potential for success.

Eligibility criteria

Inclusion Criteria:

1. Age ≥18 years.
2. Patients must have stage T1-4N+M0 or T3/T4N0M0 locally advanced anal cancer as evidenced by a PET scan AND either a CT with contrast of the abdomen/pelvis or an MRI with contrast of the pelvis. All imaging must be from within 60 days prior to registration.

   1. Note: Patients with T2N0 disease will be allowed if the primary tumor is \>4 cm. Patients with Stage I-T1N0M0 or Stage II-T2N0M0 (tumor ≤ 4cm) will be ineligible for participation.
   2. Patients with perianal cancer that is HPV associated (P16+) will be eligible if the tumor extends to the anal verge and the CTV will include the mesorectal, internal/external iliac, and inguinal lymph nodes.
   3. Patients with excision of the primary tumor but with node positive disease or residual disease at the primary if T3T4N0 will be eligible.
3. ECOG performance status 0 or 1 (or Karnofsky ≥70, see Appendix A).
4. Patients must be able to receive concurrent treatment with capecitabine and Mitomycin C in the opinion of the investigator.
5. Creatinine Clearance must be \> 30 ml/min.
6. Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

1. Any prior pelvic radiation.
2. History of allergic reactions attributed to compounds of similar chemical or biologic composition to capecitabine.
3. Patients with uncontrolled intercurrent illness that in the opinion of the investigator would prevent receipt of radiation or capecitabine.

   a. Note: HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
4. Pregnant or breastfeeding women are excluded from this study.
5. Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen in the opinion of the investigator.
6. Patients with active autoimmune or connective tissue disease requiring systemic treatment are excluded from this study.

Where this trial is running

Cincinnati, Ohio and 2 other locations

• University of Cincinnati Medical Center — Cincinnati, Ohio, United States (Recruiting)
• Ohio State University Medical Center — Columbus, Ohio, United States (Recruiting)
• University of Vermont — Burlington, Vermont, United States (Recruiting)

Study contacts

• Study coordinator: UCCC Clinical Trials Office

Conditions Anal Cancer; Toxicity Mitigation; Reduced Elective Nodal Dose